Biomarker for Rapid Diagnosis of Hemispheric Stroke "BE FAST!"


Phase N/A Results N/A

Trial Description

The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments [NR2-peptide] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.


Trial Design

  • Observation: Case-Only
  • Perspective: Prospective
  • Sampling: Probability Sample

Trial Population

Patients admitted with symptoms suspicious of acute hemispheric stroke to primary, secondary and tertiary care hospitals in Europe.


Type Measure Time Frame Safety Issue
Primary Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage) 9 months No

Biospecimen Retention:Samples Without DNA - Human plasma